Negatively charged RNase-susceptible molecules on the surface of ascites tumor cells.
RNase-susceptible ionogenic groups on the cell surface membranes of two leukemic and two nonleukemic strains of ascites tumor cells were studied by cell electrophoresis, DEAE-Sephadex A-25 column and paper chromatography, and indirect membrane immunofluorescence. RNase treatment of the nonleukemic ascites tumor cells (Ehrlich ascites tumor and Sarcoma 180) produced a significant reduction in their electrophoretic mobilities. When the cells were labeled with [3H]uridine then incubated with RNase, there was a marked increased in the radioactive nucleotides present in the incubation medium as compared to the results of the experiment with RNase-untreated controls. Indirect membrane immunofluorescence studies of nonleukemic ascites tumor cells suggest that the sites that react with anti-RNA antibody are distributed diffusely on their surfaces. RNase treatment of these cells markedly reduced their ability to react with the antibody. It thus appears that RNAs are present on the surface membrane of nonleukemic ascites tumor cells and that RNase digests these RNAs, removing negatively charged nucleotides from their electrophoretic surfaces. This results in a reduction in mobility. In contrast, leukemic ascites cells (L1210 and C1498) incubated with RNase showed no significant change in mobility or in the amount of nucleotides released into the incubation medium. Moreover, no fluorescence was found on the surface of cells examined by indirect membrane immunofluorescence. This suggests that leukemic ascites cells are devoid of RNAs on their surface.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000032:analysis; D002462:Cell Membrane / Q000032:analysis / Q000187:drug effects; D002852:Chromatography, Ion Exchange; D002854:Chromatography, Paper; D004586:Electrophoresis; D005455:Fluorescent Antibody Technique; D006801:Humans; D007939:Leukemia L1210 / Q000032:analysis; D051379:Mice; D009374:Neoplasms, Experimental / Q000032:analysis*; D012260:Ribonucleases / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000032:analysis
D012260:Ribonucleases